GREY:CLAZF - Post by User
Post by
Chritterson Aug 30, 2021 4:21pm
124 Views
Post# 33782977
Must Read
Must ReadProduct Development Program in Treatment of Acute and Chronic Pain Claritas is also developing a novel, proprietary cannabidiol (“CBD”) analogue for the treatment of acute and chronic pain. A provisional U.S. patent application for this compound is pending, and Claritas had obtained an exclusive, worldwide license for this compound from Beetlebung Pharma, Ltd. (“BPL”). However, this program has not advanced beyond the preclinical research stage, and in order to conserve cash and eliminate expenses, Claritas has placed this program on temporary hold